I have gone on to the Acrux website and emailed an investor relations request for the company to update us on the sales of the testosterone Generic in the next quarterly report. I have also asked them to let me know if they plan to give this update.
I think we are owed an update as the product has been on the market for over a year.
It's an easy process to submit a query to investor relations if you have any questions.
ACR Price at posting:
6.8¢ Sentiment: Sell Disclosure: Held
